AIQ SOLUTIONS AWARDED $2M PHASE II NIH SBIR GRANT TO ADVANCE DEVELOPMENT AND COMMERCIALIZATION OF A BIOMARKER TECHNOLOGY THAT PREDICTS CANCER IMMUNOTHERAPY RESPONSE

AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy.